ACORQ — Acorda Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.02m
- $182.13m
- $117.63m
Brief: Acorda Therapeutics Withdraws Proposal To Increase Authorized Shares From Special Meeting Of Stockholders
U.S. STOCKS ON THE MOVE-Astra Space, Ammo, Chimerix
Acorda up on licensing agreement with Asieris Pharmaceuticals
Brief: Acorda Therapeutics Enters Into License Agreement With Asieris Pharmaceuticals
Brief: Acorda Therapeutics announces resignation of chief operating officer
Brief: Acorda Therapeutics Reports Second Quarter 2022 Financial Results
Brief: Acorda Therapeutics Says On June 22, Co Got Deficiency Letter From Nasdaq Regarding Minimum Bid Requirement
Brief: Acorda Therapeutics, Inc. Provides Notice Of Data Privacy Event
Brief: Davidson Kempner Capital Management Lp Reports 9.90% Stake In Acorda Therapeutics As Of June 2 - SEC Filing
Brief: Acorda Therapeutics And Biopas Laboratories Agree To Commercialize Inbrija In Latin America
Brief: Acorda Therapeutics Reports First Quarter 2022 Financial Results
Brief: Acorda Therapeutics Q4 Non-GAAP Loss Per Share $0.67
Brief: Acorda Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results
Brief: John Varian Joins Acorda Therapeutics Board Of Directors
Acorda Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Acorda Therapeutics Announces Agreement To Commercialize Inbrija In Germany
Brief: Acorda Therapeutics Posts Q3 Loss Per Share Of $2.43
Acorda Therapeutics Inc expected to post a loss of $1.56 a share - Earnings Preview
Acorda Therapeutics Inc expected to post a loss of $1.56 a share - Earnings Preview